The Biomarkers Consortium Launches I-SPY 2 Breast Cancer Clinical Trial

Published: Mar 17, 2010

BETHESDA, Md.--(BUSINESS WIRE)--The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

Back to news